Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report

Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report

Tenofovir alafenamide (TAF) is one of the most potent first-line nucleot(s)ide analogs for treating chronic hepatitis B virus (HBV) infections. To date, no cases of TAF drug resistance and/or suboptimal response have been reported. To our knowledge, this is the first report of two adult male patient...

Full description

Bibliographic Details
Main Authors: Ruochan Chen, Siya Pei, Yayu Chen, Linxia Tan, Ying Xue, Shao Liu, Yan Huang, Xuegong Fan
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Medicine
Subjects:
tenofovir alafenamide
suboptimal response
HBeAg-positive chronic hepatitis B
monotherapy
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.701061/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.701061/full

Similar Items